Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group

The American Journal of Cardiology
E Aliot, I Denjoy

Abstract

To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study. The diagnosis of paroxysmal AF or atrial flutter had to be fully documented prior to inclusion in the study. Of the 97 patients enrolled in the study, 48 patients (25 men, 23 women, mean age 62.4 +/- 12.3 years) received flecainide; 49 patients (26 men, 23 women, mean age 63.6 +/- 12.2 years) received propafenone. The initial dose of flecainide was 50 mg twice daily, and this could be increased in steps of 50 mg twice daily every 4 days to a maximum of 300 mg/day. The initial dose of propafenone was 300 mg twice daily and this could be increased in steps of 300 mg every 4 days to a maximum of 1200 mg/day. At each visit, medical events, vital sign measurements (blood pressure, pulse rate), concomitant medications, adverse experiences, and study drug dosage changes were evaluated. Routine clinical laboratory tests were evaluated at the month 6 visit, and a 24-hr Holter recording was obtained at the month 1 visit. Almost half (45) of the patie...Continue Reading

Citations

Feb 28, 2002·Lancet·Nicholas S PetersVias Markides
Apr 16, 1999·British Journal of Pharmacology·A SekiH Kasanuki
May 30, 1998·Pacing and Clinical Electrophysiology : PACE·J KassotisJ A Reiffel
Aug 31, 2006·Current Treatment Options in Cardiovascular Medicine·Brian R Triola, Peter R Kowey
Jan 5, 2010·Biological & Pharmaceutical Bulletin·Hikaru TanakaAkira Takahara
Jan 8, 2011·Biological & Pharmaceutical Bulletin·Iyuki NamekataHikaru Tanaka
Feb 27, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Hirotsugu AtarashiUNKNOWN Flecainide Atrial Fibrillation Investigators
Mar 10, 2016·Expert Review of Cardiovascular Therapy·Tuan NguyenPeter Leong-Sit
Apr 3, 1998·The American Journal of Cardiology·C M Pratt
Feb 18, 2011·Expert Opinion on Pharmacotherapy·Alessandro Marinelli, Alessandro Capucci
Mar 16, 2001·Expert Opinion on Pharmacotherapy·J Nemec, W K Shen
Jan 9, 2013·Expert Opinion on Pharmacotherapy·Stavros ApostolakisPaulus Kirchhof
Apr 15, 2015·European Journal of Clinical Pharmacology·Juan TamargoPhillipe Mabo
Jan 14, 2011·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Nick FreemantleMatthew Reynolds
Jul 28, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Takashi KomatsuKen Okumura
Aug 23, 2000·Current Cardiology Reports·E Kongsgaard, H Aass
Mar 31, 2015·The Cochrane Database of Systematic Reviews·Carmelo Lafuente-LafuenteJoël Belmin
Feb 10, 2000·Current Opinion in Cardiology·P T Sager
Sep 5, 2019·The Cochrane Database of Systematic Reviews·Lucie ValemboisCarmelo Lafuente-Lafuente
Feb 14, 2018·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Gheorghe-Andrei DanUNKNOWN ESC Scientific Document Group
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·M Valderrábano, B N Singh
Mar 14, 2007·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Norio HashimotoNobutomo Tsuruzoe
Apr 21, 1999·Journal of Cardiovascular Electrophysiology·J E Olgin, S Viskin
May 1, 2021·Journal of Clinical Medicine·Carlo LavalleRenato Pietro Ricci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.